Back to Sites FAMCRU CRS Site Number 8950 Address Stellenbosch University KIDCRU / Ward J8 Tygerberg Hospital Francie van Zijl Ave Parow Valley Cape Town, 7505 South Africa IMPAACT Members at this Site Charise Janse van Rensburg Administrative Assistant Jacqueline Jacobs CAB Member Siphokazi Khonkwane CAB Member Jeanne De Jager CRS Coordinator Shaun Barnabas CRS Leader Mark Cotton CRS Leader Ronell Arendze CRS Staff Desmien Bagus CRS Staff Maria Bester CRS Staff Jacky Crisp CRS Staff Jeanne De Jager CRS Staff Els Dobbels CRS Staff George Fourie CRS Staff Lindee Ganger CRS Staff Leonie Groepies CRS Staff Morne Isaacs CRS Staff Patiswa Ketelo CRS Staff Lulama Kwame CRS Staff Jacqueline Martin CRS Staff Sabina Martin CRS Staff Philma Martin CRS Staff Veronica Matroos CRS Staff Bongiwe Mbotho CRS Staff Nwabisa Mtambeka CRS Staff Unine Nel CRS Staff Nosipho Ngawyi CRS Staff Susan Purchase CRS Staff Helena Rabie CRS Staff Maylene Reid CRS Staff Magdel Elizabeth Rossouw CRS Staff Roeline Sadie CRS Staff Lillian Slinger CRS Staff Kurt Smith CRS Staff Marie Theunissen CRS Staff Mercia Van Der Linde CRS Staff Warren J Zimri CRS Staff Jeannine du Bois CTU Coordinator Anneke Hesseling CTU Principal Investigator Donna Germuga DAIDS PO Candice Macola Data Management Staff Millicen Pieterse Data Management Staff Maria Groenewald Investigator Barbara Laughton Investigator Ben Marais Investigator Elke Maritz Investigator Aison Riddick Investigator Simon Schaaf Investigator Gerhard Theron Investigator Yvette Kramer Laboratory Manager/Supervisor Lindie Rossouw Pediatrician Gillian Sorour Pediatrician Catherine Andrea Pharmacist Marlize Smuts Pharmacist of Record Gertrude Boswell Research Nurse Lilly Theresa Hoorn Research Nurse Andrea Gutschmidt Staff Ayanda Ngubane Staff Wilma Orange Staff Sharifah Sylvester Staff Rochelle Sylvester Staff Anita Janse van Rensburg Study Coordinator Marije Van Schalkwyk Study Coordinator Studies at this Site IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Enrolling IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV DAIDS Number 38693 Research Area Cure and Immunotherapy Study Status Enrolling IMPAACT 2017: MOCHA DAIDS Number 30070 Research Area Therapeutics Study Status Closed to Accrual IMPAACT 2035/HVTN 604: Phase I/II Randomized, Placebo-Controlled Study of the Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination against Tuberculosis in Pre-Adolescents Living with and without HIV in South Africa (LEAP) DAIDS Number 38846 Research Area Tuberculosis Study Status Pending IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1 DAIDS Number 38962 Research Area Therapeutics Study Status In Development IMPAACT 2040: Phase I/II Pharmacokinetics and safety of long-acting injectable Cabotegravir and Rilpivirine in people with virally suppressed HIV-1 during pregnancy and postpartum DAIDS Number 38953 Research Area Therapeutics Study Status Pending IMPAACT 2039: Phase I/II Study of the Safety, Immunogenicity, and Efficacy of HIVconsvX Vaccines and Broadly Neutralizing Antibodies in Children Living with HIV DAIDS Number TBD Research Area Cure and Immunotherapy Study Status In Development Pagination Previous page Prev Page 1 Page 2 Current page 3
IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Enrolling
IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV DAIDS Number 38693 Research Area Cure and Immunotherapy Study Status Enrolling
IMPAACT 2035/HVTN 604: Phase I/II Randomized, Placebo-Controlled Study of the Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination against Tuberculosis in Pre-Adolescents Living with and without HIV in South Africa (LEAP) DAIDS Number 38846 Research Area Tuberculosis Study Status Pending
IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1 DAIDS Number 38962 Research Area Therapeutics Study Status In Development
IMPAACT 2040: Phase I/II Pharmacokinetics and safety of long-acting injectable Cabotegravir and Rilpivirine in people with virally suppressed HIV-1 during pregnancy and postpartum DAIDS Number 38953 Research Area Therapeutics Study Status Pending
IMPAACT 2039: Phase I/II Study of the Safety, Immunogenicity, and Efficacy of HIVconsvX Vaccines and Broadly Neutralizing Antibodies in Children Living with HIV DAIDS Number TBD Research Area Cure and Immunotherapy Study Status In Development